The drug maker hopes the results of a trial for Mystic, a lung-cancer treatment, will prove it was right to fend off a 2014 takeover offer and commit to developing immunotherapy medicines.
from WSJ.com: US Business http://ift.tt/2tkciqQ
via IFTTT
No comments:
Post a Comment